Unnamed: 0.1,Unnamed: 0,NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,nct_id,criteria,year,duration_years,similarity_score,rank,enrollment_size,has_results,completion_status,complexity_score,sentiment_score,common_conditions,common_interventions
17098,21786,NCT01237873,Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension,https://clinicaltrials.gov/study/NCT01237873,,COMPLETED,The purpose of this study is to evaluate the long-term safety and tolerability of the combination of aliskiren and amlodipine given to patients with essential hypertension. This study is being conducted to support registration of the fixed combination of aliskiren/amlodipine in the treatment for hypertension in Japan.,NO,Essential Hypertension,DRUG: Ali/Amlo 150/2.5 mg,"Long-term safety of the fixed-dose combination of aliskiren/ amlodipine, Measure the number patients withof AE, SAEs and analyze cahanges in safety labs., 52 weeks","Measure the change from baseline in blood pressure effects of the combination of aliskiren/ amlodipine., this endpoint will measure the change from baseline for mean sitting diastolic blood pressure, mean sitting systolic blood pressure, supine diastolic blood pressure, supine systolic blood pressure, standing diastolic blood pressure, and standing systolic blood pressure., 52 weeks|The proportion of patients achieving the blood pressure control target of <140/90 mmHg at the end of study, 52 weeks",,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,150.0,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,CSPA100A1302,2011-01,2012-02,2012-02,2010-11-10,,2017-02-23,"Novartis Investigative Site, Yokohama, Kanagawa, 231-0023, Japan|Novartis Investigative Site, Koshigaya city, Saitama, 343-0826, Japan|Novartis Investigative Site, Edogawa-ku, Tokyo, 133-0061, Japan|Novartis Investigative Site, Katsushika-ku, Tokyo, 124-0024, Japan|Novartis Investigative Site, Kiyose, Tokyo, 204-0021, Japan|Novartis Investigative Site, Kunitachi, Tokyo, 186-0001, Japan|Novartis Investigative Site, Minato-ku, Tokyo, 105-7390, Japan|Novartis Investigative Site, Minato-ku, Tokyo, 108-0075, Japan|Novartis Investigative Site, Ota-ku, Tokyo, 143-0023, Japan|Novartis Investigative Site, Shibuya-ku, Tokyo, 150-0002, Japan|Novartis Investigative Site, Shinagawa-ku, Tokyo, 141-0032, Japan|Novartis Investigative Site, Tachikawa, Tokyo, 190-0013, Japan|Novartis Investigative Site, Toshima-ku, Tokyo, 171-0021, Japan",,NCT01237873,Inclusion Criteria:~* Patients that complete CSPA100A1301 study~* Patients whose blood pressure at Visit 7 of CSPA100A1301 study must be well controlled~Exclusion Criteria:~* Patients who experienced any serious adverse events considered drug related in CSPA100A1301 study~* Presence of major protocol violation in CSPA100A1301 study~Other protocol-defined inclusion/exclusion criteria may apply,,,0.99102736,1,150.0,1.0,COMPLETED,3.19,0.05,0,0
32068,40819,NCT00809926,8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension,https://clinicaltrials.gov/study/NCT00809926,VANTAGE,COMPLETED,To evaluate the efficacy and safety of the valsartan/aliskiren combination compared to valsartan alone in patients with Stage 2 hypertension.,YES,Stage 2 Hypertension,DRUG: Valsartan/aliskiren|DRUG: Valsartan,"Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8, To compare the change from baseline in MSSBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension., Baseline to Week 8","Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8, To compare the change in MSDBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan (160 mg, 320 mg) treatment regimen in patients with Stage 2 Hypertension., Baseline to Week 8|Percentage of Patients Achieving Blood Pressure Control (Defined as Patients Achieving a MSSBP <140 mmHg and MSDBP <90 mmHg) at Week 8, To evaluate the percentage of patients achieving blood pressure control (defined as patients achieving a MSSBP \<140 mmHg and MSDBP \<90 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension., At Week 8|Percentage of Responders (Defined as Patients With MSSBP <140 mmHg or a Decrease From Baseline ≥20 mmHg) at Week 8, To compare the percentage of responders (defined as patients with MSSBP \<140 mmHg or a decrease from baseline ≥20 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension., At Week 8|Mean Change From Baseline in Plasma Renin Activity (PRA) at Week 8, To assess the change from baseline in PRA after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension., Baseline to Week 8|Mean Change From Baseline in Plasma Renin Concentration (PRC) at Week 8, To assess the change from baseline in PRC after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension., Baseline to Week 8","Completers Analysis for Change From Baseline in MSSBP at Week 8, To evaluate the change from baseline in MSSBP (mmHg) at Week 8; primary efficacy variable at primary time point in ITT population - patients who completed the double-blind treatment period., Baseline to week 8|Longitudinal Repeated Measure Analysis for Change in MSSBP From Baseline Through Week 8, To evaluate the change from baseline in MSSBP (mmHg) after 8 weeks; primary efficacy variable (ITT population) using Longitudinal analysis (A repeated measures analysis where assessments over time are considered , as opposed to looking at a single point in time.), Baseline through week 8|Change From Baseline in Mean Ambulatory Systolic Blood Pressure (MASBP)., To evaluate 24-hour ambulatory systolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension., Baseline to week 8|Change From Baseline in Mean Ambulatory Diastolic Blood Pressure (MADBP), To evaluate 24-hour ambulatory diastolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension., Baseline to week 8",Novartis,,ALL,"ADULT, OLDER_ADULT",PHASE4,451.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",CSPV100AUS01,2009-01,2009-07,2009-07,2008-12-17,2011-05-02,2011-05-02,"Sites in USA, East Hanover, New Jersey, 07936, United States",,NCT00809926,"Inclusion Criteria:~* Patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.~* Men or women 18 years and older.~* Patients with Stage 2 systolic hypertension; defined as having a MSSBP ≥160 mmHg and \<180 mmHg at Visit 5 (randomization).~Exclusion Criteria:~* Use of aliskiren or participation in a clinical trial that had aliskiren as treatment within 30 days of Visit 1.~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>5 mIU/ml).~* Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception (implantable, patch, oral), and double-barrier methods. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.~* Severe hypertension (an office cuff MSDBP ≥110 mmHg and/or MSSBP ≥180 mmHg).~* Refractory hypertension, defined as unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmHg).~* Patients treated with more than 3 antihypertensive medications (each component of a combination drug counts individually).~* History or evidence of a secondary form of hypertension.",,,0.9906848,2,451.0,1.0,COMPLETED,1.41,0.0,0,0
36780,46745,NCT02690974,Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting,https://clinicaltrials.gov/study/NCT02690974,PARASAIL,COMPLETED,"The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection fraction (HFrEF) in Canada.

The study was also to describe the overall tolerability, effectiveness and safety of LCZ696 for the management of HFrEF over 12 months of treatment, as well as describe the patterns of LCZ696 up and down dose titrations occurring during the management of patients with HFrEF.",YES,Hearth Failure With Reduced Ejection Fraction (HFrEF),DRUG: LCZ696 (sacubitril/valsartan),"Percentage of Participants on LCZ696 200 mg Bid at Month 6, The tolerability of LCZ696 was defined as the percentage of patients on LCZ696 at the dose of 97 mg sacubitril / 103 mg valsartan twice daily (bid) who did not experience down titration or treatment discontinuation because of adverse events while on this dose at month 6. Only descriptive analysis done., Month 6","Percentage of Participants on LCZ696 200 mg Bid at Month 12, The tolerability of LCZ696 was defined as the percentage of patients on LCZ696 at the dose of 97 mg sacubitril / 103 mg valsartan twice daily (bid) who did not experience down titration or treatment discontinuation because of adverse events while on this dose at month 12. Only descriptive analysis done., Month 12|Percentage of Participants Requiring Down-titration From LCZ696 200 mg, The impact of the titration scheme on the tolerability of patients maintained on LCZ696 97 mg sacubitril / 103 mg valsartan bid was defined as the percentage of patients on LCZ696 200mg requiring down-titration. Only descriptive analysis done., Month 12|Percentage of Participants With Down-titration Changes From LCZ696 200 mg During 12 Months of Treatment, The impact of the titration scheme on the tolerability of patients maintained on LCZ696 97 mg sacubitril / 103 mg valsartan bid was defined as the number of down-titration during the 12 months treatment period. Dow-titration schemes considered for the analysis are 200 mg to 100 mg; 100 mg to 50 mg; and 50 mg to 0 mg (i.e. treatment discontinuation). The down-titration scheme of 50mg to 0 mg was taken in account in this analysis to ensure to reflect all actual changes in dose. Only descriptive analysis done., Month 12|Change From Baseline in the Six Minute Walk Test (6MWT) at Month 6 and Month 12, The impact of LCZ696 on functional exercise capacity was measured by the Six Minute Walk Test at 6 and 12 months. The 6MWT measures the distance an individual is able to walf over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. Only descriptive analysis done., Baseline, Month 6 and Month 12|Time to Each Up-titration to LCZ696 100 mg and LCZ696 200 mg, To describe the time of up-titration for each dose (24 mg sacubitril / 26 mg valsartan bid and 49 mg sacubitril / 51 mg valsartan bid) of LCZ696. Only descriptive analysis done., Baseline, Week 2, Week 4, Month 3, Month 6 and Month 12|Median Time to Reach LCZ696 200 mg, To describe the time of up-titration for each dose (24 mg sacubitril / 26 mg valsartan bid and 49 mg sacubitril / 51 mg valsartan bid) of LCZ696. Only descriptive analysis done., Baseline, Week 2, Week 4, Month 3, Month 6 and Month 12|Percentage of Participants on Guideline Recommended Dose of Beta-blockers and MRAs Over Time, To describe the adherence to guideline recommended dosing of beta-blockers and MRAs at 6 and 12 months of treatment of LCZ696. Only descriptive analysis done., Baseline, Month 6 and Month 12",,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE4,302.0,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,CLCZ696BCA02,2016-03-08,2017-06-07,2017-11-29,2016-02-24,2019-06-07,2019-06-07,"Novartis Investigative Site, Edmonton, Alberta, T5H 3V9, Canada|Novartis Investigative Site, New Westminster, British Columbia, V3L 3W4, Canada|Novartis Investigative Site, Vancouver, British Columbia, V6Z 1Y6, Canada|Novartis Investigative Site, Winnipeg, Manitoba, R2H 2A6, Canada|Novartis Investigative Site, Moncton, New Brunswick, E1C 2Z3, Canada|Novartis Investigative Site, Moncton, New Brunswick, E1G 1A7, Canada|Novartis Investigative Site, St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Novartis Investigative Site, Burlington, Ontario, L7M 4Y1, Canada|Novartis Investigative Site, Cambridge, Ontario, N1R 6V6, Canada|Novartis Investigative Site, London, Ontario, N6A 5A5, Canada|Novartis Investigative Site, Mississauga, Ontario, L5K 2L3, Canada|Novartis Investigative Site, Newmarket, Ontario, L3Y 2P6, Canada|Novartis Investigative Site, Newmarket, Ontario, L3Y 8C3, Canada|Novartis Investigative Site, Ottawa, Ontario, K1Y 4W7, Canada|Novartis Investigative Site, Peterborough, Ontario, K9J 0B2, Canada|Novartis Investigative Site, Sarnia, Ontario, N7T 4X3, Canada|Novartis Investigative Site, Scarborough, Ontario, M1E 5E9, Canada|Novartis Investigative Site, Scarborough, Ontario, M1P 2V5, Canada|Novartis Investigative Site, Sudbury, Ontario, P3E 3B8, Canada|Novartis Investigative Site, Sudbury, Ontario, P3E 5M9, Canada|Novartis Investigative Site, Toronto, Ontario, M6R 1B5, Canada|Novartis Investigative Site, Waterloo, Ontario, N2T 0C1, Canada|Novartis Investigative Site, Weston, Ontario, M9N 1W4, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2G8, Canada|Novartis Investigative Site, Joliette, Quebec, J6E 6J2, Canada|Novartis Investigative Site, Montreal, Quebec, H1T 3Y7, Canada|Novartis Investigative Site, St-Jean-sur-Richelieu, Quebec, J3A 1J2, Canada|Novartis Investigative Site, Terrebonne, Quebec, J6V 2H2, Canada|Novartis Investigative Site, Brossard, J4Z 2K9, Canada|Novartis Investigative Site, Hamilton, L8L 0A9, Canada|Novartis Investigative Site, Quebec, GIV 4G5, Canada|Novartis Investigative Site, St-Lambert, J4P 2J2, Canada","Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/74/NCT02690974/SAP_000.pdf|Study Protocol, https://cdn.clinicaltrials.gov/large-docs/74/NCT02690974/Prot_001.pdf",NCT02690974,"Key Inclusion Criteria:~1. Written informed consent must be obtained before any assessment is performed.~2. Age ≥ 18 years and ≤ 80 years.~3. Males or females.~4. Diagnosis of Heart Failure NYHA class II-III.~5. Diagnosis of Heart Failure with reduced Ejection Fraction (LVEF =\< 40%) and NYHA class II or III.~6. Stable on any dose of ACEI or ARB prior to enrolment in the study~7. Stable on any dose of a beta-blocker prior to enrolment in the study.~8. Eligible for treatment with LCZ696 as per Canadian product monograph.~9. Treated as an outpatient.~10. Signed an informed consent agreeing to participate in the study.~Key Exclusion Criteria:~1. Symptomatic hypotension and/or a SBP \< 100 mmHg at baseline visit.~2. Estimated GFR \< 30 mL/min/1.73m\^2 as measured by the simplified Modification of Diet in Renal Disease (MDRD) formula at baseline visit.~3. Known history of angioedema related to previous ACEI or ARBs therapy, or history of hereditary or idiopathic angioedema.~4. Requirement of concomitant treatment with both ACEIs and ARBs.~5. Concurrent participation in other clinical trials or receiving other investigational drugs within 30 days of enrollment.~6. Hypersensitivity to the active substances, sacubitril or valsartan, or to any of the excipients.~7. Concomitant use of aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR \<60ml/min/1.73m\^2).~8. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.~9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.~11. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment. Effective contraception methods are described in the protocol.",2016.0,1.0,0.99052435,3,302.0,1.0,COMPLETED,5.32,-0.018,0,0
67904,86310,NCT01392534,Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting,https://clinicaltrials.gov/study/NCT01392534,POTASSIUM,COMPLETED,"One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion. Disregulation of plasma potassium may be a life-threatening condition due to increased risk of arrythmias. Moreover, it has been postulated that decrease in plasma potassium level may negatively affect glucose metabolism resulting in the increased risk of new-onset type 2 diabetes.The main goal of this study is to assess the efficacy and safety of telmisartan/hydrochlorothiazide in a broad population of hypertensive patients, including the effects of the therapy on plasma potassium level and also on selected parameters of glucose and lipid metabolism.",NO,Primary Hypertension,"DRUG: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)","Change in systolic (SBP) and diastolic (DBP) blood pressure between first and final visit, approx. 3 mths after telmisartan/hydrochlorothiazide treatment initiation","Change in plasma potassium between initial and final visit, approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation|Change in fasting plasma glucose between initial and final visit, approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation|Change in glycated haemoglobin A1C between initial and final visit, approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation|Change in plasma high density lipoprotein between initial and (continued), approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation|Change in plasma low density lipoprotein between initial and final visit, approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation|Change in plasma cholesterol between initial and final visit, approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation|Change in plasma triglycerides between initial and final visit, approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation|Adverse events collection, approx 3 mths after telmisartan/hydrochlorothiazide treatment initiation",,Bayer,,ALL,"ADULT, OLDER_ADULT",,1586.0,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,15297|KL1010PL,2010-07,2010-12,2010-12,2011-07-12,,2012-07-04,"Many Locations, Poland",,NCT01392534,Inclusion Criteria:~* primary hypertension~* age\>18 years~Exclusion Criteria:~* Cholestatic disorders or severe hepatic/renal failure~* allergy to telmisartan or hydrochlorothiazide~* treatment-resistant hypokalemia or hypercalcemia~* pregnancy and lactation period,,,0.99044275,4,1586.0,1.0,COMPLETED,7.16,0.001,0,0
9040,11486,NCT00927394,Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus,https://clinicaltrials.gov/study/NCT00927394,ViVID,COMPLETED,"The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II hypertension.",YES,Hypertension,DRUG: Aliskiren|DRUG: Valsartan|DRUG: Placebo for Aliskiren|DRUG: Placebo for Valsartan,"Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8, The 24-hour ambulatory systolic blood pressure was evaluated at baseline (Week 0) and post-baseline visits. The mean hourly systolic blood pressure was calculated at post-dosing hours 1-24 for each patient. The MASBP for each patient was calculated by averaging the patient's available hourly means for post-dosing hours 1-24., baseline, week 8","Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP), Sitting blood pressure was measured at trough (24 hours ± 3 hours post dose) and recorded at all study visits. At the first study visit, the arm in which the highest sitting diastolic blood pressure was found was the arm used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for five minutes, systolic and diastolic blood pressures were measured 3 times using the standard mercury sphygmomanometer. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting office blood pressure for that visit., Baseline, week 8|Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (MADBP) at Week 8, The 24-hour ambulatory diastolic blood pressure was evaluated at baseline (Week 0) and post-baseline visits. The mean hourly diastolic blood pressure was calculated at post-dosing hours 1-24 for each patient. The MADBP for each patient was calculated by averaging the patient's available hourly means for post-dosing hours 1-24., baseline, week 8|Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (MAPP) at Week 8, The 24-hour ambulatory pulse pressure was evaluated at baseline (Week 0) and post-baseline visits., baseline, week 8|Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP), Sitting blood pressure was measured at trough (24 hours ± 3 hours post dose) and recorded at all study visits. At the first study visit, the arm in which the highest sitting diastolic blood pressure was found was the arm used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for five minutes, systolic and diastolic blood pressures were measured 3 times using the standard mercury sphygmomanometer. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting office blood pressure for that visit., Baseline, week 8|Change From Baseline in Mean Sitting Pulse Pressure (MSPP) at Week 8, At each visit, the pulse rate was measured for 30 seconds just prior to the first sitting blood pressure measurement., baseline, week 8|Percentage of Patients Achieving Blood Pressure Control, Blood pressure control was defined as MSSBP/MSDBP \<140/90 mmHg. Percentage of patients achieving of blood pressure control at the corresponding visit was reported, 8 weeks|Percentage of Responders, Responders were defined as patients with MSSBP \<130 mmHg or a reduction from baseline in MSSBP of \>20 mmHg.Percentage of responders achieving a response at the corresponding visit was reported., Baseline, Week 8|Change From Baseline in Plasma Renin Activity (PRA) at Week 8, Baseline, week 8|Change From Baseline in Plasma Renin Concentration (PRC) at Week 8, Baseline, week 8|Change From Baseline in Plasma Aldosterone at Week 8, Baseline, week 8|Number of Patients With Adverse Events, Serious Adverse Events and Death, Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen.

Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards., 8 weeks",,Novartis,,ALL,"ADULT, OLDER_ADULT",PHASE4,1143.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CSPV100AUS02,2009-05,2011-10,2011-10,2009-06-25,2012-10-31,2012-12-06,"Investigative Site, Newark, Delaware, USA, United States|Investigative Site, Kansas, Missouri, United States|Investigative Site, Camden, New Jersey, United States|Investigative Site, Philadelphia, Pennsylvania, United States",,NCT00927394,"Inclusion Criteria:~* Patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.~* Men or women 18 years and older.~* Patients with Type 2 diabetes mellitus with an HbA1c ≤ 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1.~Cohort 1:~* Patients with Stage 2 systolic hypertension, defined as having a MSSBP ≥160 mmHg and \<200 mmHg at Visit 5 (randomization).~* Patients who have been newly diagnosed with hypertension or who have not received antihypertensive medication for at least 4 weeks (28 days) prior to Visit 1 must have MSSBP ≥ 160 mmHg and \< 200 mmHg at Visit 1, otherwise, they will be considered screen failures.~* Patients receiving antihypertensive medication must have a MSSBP of ≥150 mmHg and \<200 mmHg at Study Visit 1, otherwise they will be considered screen failures.~Cohort 2:~* Patients must also have had a mean 8-hour daytime ambulatory systolic blood pressure (ASBP) ≥140 mmHg AND mean 8-hour daytime ambulatory diastolic blood pressure (ADBP) ≥90 mmHg at Visit 5 (randomization).~* Hypertensive patients with MSSBP ≥150 mmHg and but \<200 mmHg AND MSDBP ≥95 but \<120 mmHg at Visit 5 (randomization).~* Patients who had been newly diagnosed with hypertension or who had not received antihypertensive medication for at least 4 weeks (28 days) prior to Visit 1 must have had MSSBP ≥150 mmHg but \<200 mmHg and MSDBP ≥95 but \<120 mmHg at Visit 1, otherwise, they were considered screen failures.~Exclusion Criteria:~* Office blood pressure measured by cuff (MSSBP ≥200 mmHg or MSDBP ≥120 mmHg).~* History or evidence of secondary hypertension of any etiology.~* Refractory hypertension, defined as having uncontrolled BP (≥140/90 mmHg) while receiving 3 antihypertensive medications at the maximum approved dose of each drug, one of which must be a diuretic.~* Patients treated with more than 3 antihypertensive medications (each component of a combination drug counts individually).~* Type 2 diabetes mellitus currently requiring insulin treatment.~* modification of diet in renal disease (MDRD) estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2~* Serum sodium less than lower limit of normal, serum potassium \< 3.5 mEq/L or ≥ 5.3 mEq/L at Visit 1.~* Known Keith-Wagener grade III or IV hypertensive retinopathy.~Cohort 1:~- Patients with known diabetic retinopathy (eg, having a history of laser therapy for diabetic retinopathy) or diabetic neuropathy (eg, receiving medication for diabetic neuropathy).~Cohort 2:~- Patients with known diabetic retinopathy or diabetic neuropathy and/or having a history of treatment for either.~Other protocol-defined inclusion/exclusion criteria applied.",,,0.9899533,5,1143.0,1.0,COMPLETED,2.4,0.0,1,0
61957,78779,NCT00416468,Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.,https://clinicaltrials.gov/study/NCT00416468,,COMPLETED,This study will assess the bioavailability of aliskiren and valsartan as a single tablet compared to the same doses of the two drugs given as two separate tablets in healthy subjects.,NO,Healthy,DRUG: Aliskiren|DRUG: Valsartan,The relative bioavailability of the fixed dose combination of aliskiren/valsartan versus the free combination of aliskiren and valsartan via PK samples at pre-determined time points from pre-dose to 96 hours post-dose.,To characterize the fixed dose combination of aliskiren/valsartan via Pk samples at pre-determines time points.|The safety and tolerability of a single oral dose of a fixed and free combination aliskiren/valsartan.,,Novartis,,ALL,ADULT,PHASE1,32.0,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,CSPV100A2101,2006-11,,,2006-12-28,,2007-06-22,"Novartis Investigative Site, East Hanover, New Jersey, 07936-1080, United States",,NCT00416468,"Inclusion Criteria:~* Healthy female subjects age 18 to 45 years (inclusive) in good health as determined by past medical history, physical examination, vital signs assessments, electrocardiogram, and laboratory tests at screening and baseline..~* Female subjects of child bearing potential must be using a double-barrier local contraception i.e. intra-uterine device plus condom, or spermicidal gel plus condom for at least 3 months prior to Study start or postmenopausal females must have had no regular menstrual bleeding for at least 1 year prior to inclusion (Menopause will be confirmed by a plasma FSH level of \>40 IU/L) or female subjects must have been surgically sterilized at least 6 months prior to screening with supportive clinical documentation.~and all female subjects must have negative pregnancy results at screening and each baseline (regardless of reported reproductive status).~* Body mass index (BMI) must be 18 - 30 kg/m2 (inclusive) and subjects must weigh at least 50 kg.~* Vital signs should be within the following ranges: oral body temperature between 35.0-37.5 °C, systolic blood pressure, 90-140 mm Hg, diastolic blood pressure, 50-90 mm Hg, pulse rate, 40 - 90 beats per minute (bpm)~Exclusion Criteria:~* Smokers (use of tobacco products within the previous 3 months). Smokers will be defined who reports tobacco use or has a urine cotinine value of ≥ 300 ng/mL.~* Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Acetominophen is acceptable, with supportive clinical documentation..~* Participation in any clinical investigation within a minimum of 4 weeks prior to dosing (or longer if local regulations apply).~* Significant illness within the 2 weeks prior to dosing.~* Lactating and breast feeding females.~Other protocol-defined inclusion/exclusion criteria may apply",,,0.9898865,6,32.0,1.0,COMPLETED,1.83,0.143,0,0
45376,57664,NCT01151410,"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",https://clinicaltrials.gov/study/NCT01151410,,COMPLETED,"The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with hypertension (msSBP ≥ 95th percentile for age, gender and height, at baseline in study CSPP100A2365). Patients will be randomized to receive either aliskiren or enalapril. Weight-group based doses of aliskiren or enalapril will be administered once daily and children will receive study medication in a double-blind manner. This study is being conducted to support monotherapy registration of aliskiren for the treatment of hypertension in pediatric patients 6-17 years of age (age at baseline in Study CSPP100A2365).",YES,Hypertension,DRUG: Aliskiren|DRUG: Enalapril,"Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at to End of Study, Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit., Baseline - end of study (Week 52 or Last observation carried forward (LOCF)","Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study, Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit., Baseline - end of study (Week 52 or Last observation carried forward (LOCF)|Change in Mean Arterial Pressure (MAP) (mmHg) From Baseline to End of Study, MAP was defined as the average arterial pressure during a single cardiac cycle. The MAP was measured as sum of diastolic blood pressure (DBP) and one third of difference between systolic blood pressure (SBP) and DBP i.e. MAP = DBP+1/3\*(SBP--DBP)., Baseline to end of study (Week 52 or LOCF)",,Novartis Pharmaceuticals,,ALL,CHILD,PHASE3,208.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CSPP100A2365E1|2009-017029-20,2010-08,2015-08,2015-08,2010-06-28,2016-03-07,2016-03-07,"Novartis Investigative Site, Birmingham, Alabama, 35294-0006, United States|Novartis Investigative Site, Little Rock, Arkansas, 72202, United States|Novartis Investigative Site, Los Angeles, California, 90048, United States|Novartis Investigative Site, Dalton, Georgia, 30721, United States|Novartis Investigative Site, Lewiston, Idaho, 83501, United States|Novartis Investigative Site, Park Ridge, Illinois, 60068, United States|Novartis Investigative Site, Louisville, Kentucky, 40202, United States|Novartis Investigative Site, Hattiesburg, Mississippi, 39401, United States|Novartis Investigative Site, Jackson, Mississippi, 39209, United States|Novartis Investigative Site, New York, New York, 10016, United States|Novartis Investigative Site, Columbus, Ohio, 43205, United States|Novartis Investigative Site, Toledo, Ohio, 43606, United States|Novartis Investigative Site, Portland, Oregon, 07227, United States|Novartis Investigative Site, Portland, Oregon, 97225, United States|Novartis Investigative Site, Charleston, South Carolina, 29425, United States|Novartis Investigative Site, Amarillo, Texas, 79106, United States|Novartis Investigative Site, Charleston, West Virginia, 25304, United States|Novartis Investigative Site, Guatemala City, 01010, Guatemala|Novartis Investigative Site, Budapest, 1083, Hungary|Novartis Investigative Site, Budapest, 1131, Hungary|Novartis Investigative Site, Debrecen, 4032, Hungary|Novartis Investigative Site, Miskolc, 3529, Hungary|Novartis Investigative Site, Nyiregyhaza, 4400, Hungary|Novartis Investigative Site, Szeged, 6725, Hungary|Novartis Investigative Site, Veszprem, H-8200, Hungary|Novartis Investigative Site, Warszawa, 04-154, Poland|Novartis Investigative Site, San Juan, 00907, Puerto Rico|Novartis Investigative Site, Bratislava, 84103, Slovakia|Novartis Investigative Site, Bratislava, 85107, Slovakia|Novartis Investigative Site, Martin, 03601, Slovakia|Novartis Investigative Site, Myjava, 90701, Slovakia|Novartis Investigative Site, Presov, 08001, Slovakia|Novartis Investigative Site, Trnava, 91701, Slovakia|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Ankara, 06490, Turkey|Novartis Investigative Site, Ankara, 06500, Turkey",,NCT01151410,"Inclusion Criteria:~* msSBP (mean of 3 systolic blood pressure measurements) must be ≥ 95th percentile for age, gender and height, at Visit 2 (randomization), in study CSPP100A2365~* Must be ≥ 20 kg and ≤ 150 kg at Visit 2 (randomization), in study CSPP100A2365~* Must be able to swallow minitablets (2mm in diameter) administered in soft food~* Successful completion of Phase 1 (dose response phase) and at least 1 week of Phase 2 (placebo withdrawal phase) of the CSPP100A2365 protocol, with no serious drug-related adverse event(s).~Exclusion Criteria:~* Patient receiving immunosuppressant medication (e.g. cyclosporine, MMF, etc) other than oral/topical steroids, for any medical condition~* Current diagnosis of heart failure (NYHA Class II-IV) or history of cardiomyopathy or obstructive valvular disease~* msSBP ≥ 25% above the 95th percentile~* Second or third degree heart block without a pacemaker~* AST/SGOT or ALT/SGPT \>3 times the upper limit of the reference range~* Total bilirubin \> 2 times the upper limit of the reference range~* Creatinine clearance \< 30 mL/min/1.73m² (calculated using Modified Schwartz formula to estimate glomerular filtration rate \[GFR\]), based on the serum creatinine concentration obtained at the screening visit)~* WBC count \< 3000/mm³~* Platelet count \< 100,000/mm³~* Serum potassium \> 5.2 mEq/L~* Other protocol-defined inclusion/exclusion criteria may apply",,,0.9896024,7,208.0,1.0,COMPLETED,7.45,-0.011,1,0
71990,91519,NCT00705575,Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension,https://clinicaltrials.gov/study/NCT00705575,ACQUIRE,COMPLETED,This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of 12 weeks.,YES,Hypertension,DRUG: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|DRUG: Aliskiren (300 mg),"Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 12), At the first visit, blood pressure (BP) was measured in both arms and the arm having the higher BP reading was the arm used for all subsequent readings throughout the study. Patients were required to sit for five minutes with feet flat on the floor, with arm resting so that the bottom of the cuff was at the same level as the heart. BP was measured three times at 1 to 2-minute intervals at each visit using the correct cuff size. The mean BP was calculated from the 3 readings., Baseline to end of study (Week 12)","Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8, At the first visit, blood pressure (BP) was measured in both arms and the arm having the higher BP reading was the arm used for all subsequent readings throughout the study. Patients were required to sit for five minutes with feet flat on the floor, with arm resting so that the bottom of the cuff was at the same level as the heart. BP was measured three times at 1 to 2-minute intervals at each visit using the correct cuff size. The mean BP was calculated from the 3 readings., Baseline to Week 8|Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 8 and to Week 12, At the first visit, blood pressure (BP) was measured in both arms and the arm having the higher BP reading was the arm used for all subsequent readings throughout the study. Patients were required to sit for five minutes with feet flat on the floor, with arm resting so that the bottom of the cuff was at the same level as the heart. BP was measured three times at 1 to 2-minute intervals at each visit using the correct cuff size. The mean BP was calculated from the 3 readings., Baseline to Week 12|Percentage of Patients Achieving the Target Blood Pressure (msSBP < 140 mm Hg and msDBP < 90 mm Hg, and msSBP < 130 mm Hg and msDBP < 80 mm Hg for Diabetics) at Week 8 and Week 12, At the first visit, blood pressure (BP) was measured in both arms and the arm having the higher BP reading was the arm used for all subsequent readings throughout the study. Patients were required to sit for five minutes with feet flat on the floor, with arm resting so that the bottom of the cuff was at the same level as the heart. BP was measured three times at 1 to 2-minute intervals at each visit using the correct cuff size. The mean BP was calculated from the 3 readings., Baseline to Week 12",,Novartis,,ALL,"ADULT, OLDER_ADULT",PHASE3,688.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",CSPP100A2353,2008-06,2009-04,2009-04,2008-06-26,2011-01-21,2011-05-30,"Investigative Site, East Hanover, New Jersey, 07936, United States|Investigative Site, Buenos Aires, Argentina|Investigative Site, Quito, Ecuador|Investigative Site, Berlin, Germany|Investigative Site, Guatemala City, Guatemala|Investigative Site, Rome, Italy|Investigative Site, Basel, Switzerland|Investigative Site, Ankara, Turkey",,NCT00705575,"Inclusion Criteria:~* Outpatients ≥18 years of age.~* Patients with a diagnosis of Stage II hypertension, defined as mean sitting Systolic Blood Pressure (msSBP) ≥ 160 mmHg and \< 180 mmHg at Visit 2.~Exclusion Criteria:~* Severe hypertension defined as msSBP ≥ 180 mmHg and/or mean sitting Diastolic Blood Pressure (msDBP) ≥ 110 mmHg.~* Secondary form of hypertension.~* Current diagnosis of heart failure (New York Heart Association \[NYHA\] Class II-IV).~* Current angina pectoris requiring pharmacological therapy (other than stable doses of oral or topical nitrates).~* Second or third degree heart block without a pacemaker.~* Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia, atrial fibrillation or atrial flutter, during the 12 months prior to Visit 1.~* Clinically significant valvular heart disease.~* Previous history of hypertensive encephalopathy or stroke, Transcient Ischemic Attack (TIA), heart attack, coronary bypass surgery or any PCI.~* Known Keith-Wagener grade III or IV hypertensive retinopathy.~* In the month prior to Visit 1, patients on combination antihypertensive therapy that includes more than 2 classes of antihypertensive medications.~* Patients on combined antihypertensive medication that contain two classes of antihypertensive medications are considered to take two antihypertensive medications.~* Inability to discontinue prior antihypertensive or other CV medications as required by the protocol.~* Patients with Type 1 diabetes mellitus.~* Patients with Type 2 diabetes mellitus not well controlled .~* Elevated Serum potassium (over 5.3 mEq/L (mmol/L).~* Any surgical or medical condition or the use of any medication which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs.~Other protocol-defined inclusion/exclusion criteria may apply.",,,0.9895339,8,688.0,1.0,COMPLETED,2.37,0.0,1,0
11428,14511,NCT02620163,Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment,https://clinicaltrials.gov/study/NCT02620163,,COMPLETED,To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment,NO,Hypertension,DRUG: telmisartan/amlodipine 40/5mg|DRUG: YH22162 40/5/12.5 mg|DRUG: telmisartan/amlodipine 80/5mg|DRUG: YH22162 80/5/25 mg|DRUG: telmisartan/amlodipine 40/5mg placebo|DRUG: YH22162 40/5/12.5 mg placebo|DRUG: telmisartan/amlodipine 80/5mg placebo|DRUG: YH22162 80/5/25 mg placebo,"Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8, baseline and week 8","Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 2, baseline and week 2|Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4, baseline and week 4|Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 2, baseline and week 2|Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 4, baseline and week 4|Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 8, baseline and week 8|Patients Achieving Blood Pressure Control at Week 2, Mean sitting blood pressure(MSBP) \< 140/90 mmHg, baseline and week 2|Patients Achieving Blood Pressure Control at Week 4, Mean sitting blood pressure(MSBP) \< 140/90 mmHg, baseline and week 4|Patients Achieving Blood Pressure Control at Week 8, Mean sitting blood pressure(MSBP) \< 140/90 mmHg, baseline and week 8|Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 2, reduction of MSSBP\>= 20 mmHg and reduction of MSSBP\>= 10 mmHg, baseline and week 2|Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 4, reduction of MSSBP\>= 20 mmHg and reduction of MSSBP\>= 10 mmHg, baseline and week 4|Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 8, reduction of MSSBP\>= 20 mmHg and reduction of MSSBP\>= 10 mmHg, baseline and week 8",,Yuhan Corporation,,ALL,"ADULT, OLDER_ADULT",PHASE3,381.0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",YH22162-301,2015-12,2016-12,2016-12,2015-12-02,,2019-03-11,"Yuhan, Seoul, Korea, Republic of",,NCT02620163,"Inclusion Criteria:~* Signed Informed Consent~* Men and women ≥ 19 years of age~* Essential hypertensive patients~  1. If already taking antihypertensive drugs, mean sitting systolic blood pressure (MSSBP) must be 140 mmHg ≤ MSSBP \< 200 mmHg~ 2. If not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic blood pressure (MSSBP) must be 160 mmHg ≤ MSSBP \< 200 mmHg~Exclusion Criteria:~* Patients with known or suspected secondary hypertension~* Other exclusions applied",,,0.98952174,9,381.0,1.0,COMPLETED,1.77,0.0,1,0
30973,39385,NCT01070030,Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension,https://clinicaltrials.gov/study/NCT01070030,ACADEMY,COMPLETED,This study assessed the efficacy and safety of combination therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in patients with stage II Hypertension.,NO,Stage II Hypertension,"DRUG: Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)","Percentage of participants with stage II hypertension achieving blood pressure (BP) goal, The BP goal for non-diabetic patient is defined as msSBP \< 140 mmHg and msDBP \< 90 mmHg. The BP goal for diabetic patient is msSBP \< 130 mmHg and msDBP \< 80 mmHg) in patients with stage II hypertension., 18 weeks","Percentage of participants who have blood pressure surge to their baseline level during 24-h ambulatory blood pressure monitor (ABPM), 24-h ABPM profiles were assessed by percentage of participants who have blood pressure (BP) surge to their baseline level (during 24-h ABPM) once after patients achieve BP goal (BP goal for non-diabetic patient is defined as msSBP \< 140 mmHg and msDBP \< 90 mmHg; and the BP goal for diabetic patient is msSBP \< 130 mmHg and msDBP \< 80) at any visit only in selected study sites. The mean 24-hour MADBP (Mean Ambulatory Diastolic Blood Pressure) or MASBP (Mean Ambulatory Systolic Blood Pressure) is defined as the average of the hourly MADBP or MASBP over 24 hours respectively., 18 weeks|Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to study end, mSBP and mDBP is defined as an average of 2 points blood pressure measurements which 5 minutes apart. Patient must be at rest for at least 5 minutes in sitting position before the heart rate and blood pressure measurement. The arm for blood pressure measurement should be the same during the whole study., From baseline to study completion (between week 8 to 18)|Number of participants with responder rate for Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP), The responder rate of msSBP is defined as msSBP \< 140 mmHg for non-diabetic patients (msSBP \< 130 mmHg for diabetic patients) or by a reduction of ≥ 20 mmHg BP from baseline.

The responder rate of msDBP is defined as msDBP \< 90 mmHg for non-diabetic patients ( msDBP \< 80 mmHg for diabetic patients) or by a reduction of ≥ 10 mm Hg BP from baseline, 18 weeks|Number of patients with any adverse events, An adverse event can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the medicinal (investigational) product., 18 weeks",,Novartis,,ALL,"ADULT, OLDER_ADULT",PHASE4,230.0,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,CSPP100ATH01,2010-01,2010-10,2010-10,2010-02-17,,2017-02-23,"Investigative Site, Bangkok, Thailand|Investigative Site, Chiang Mai, Thailand|Investigative Site, Nakhon Ratchasima, Thailand",,NCT01070030,"Inclusion Criteria:~* Outpatients 18 years of age or older~* Male or female patients are eligible. Female patients must be either post-menopausal for one year, surgically sterile, or using effective contraceptive methods such as oral contraceptives, barrier method with spermicidal or an intrauterine device.~* Patients with a diagnosis of hypertension as following msDBP \& msSBP Requirements:~  * For newly diagnosed/untreated patients:~    * Mean Sitting Diastolic Blood Pressure (msDBP) ≥ 100 and \< 120 mmHg, and/or mean sitting Systolic Blood Pressure (msSBP) ≥ 160 and \< 200 mmHg at Visit1.~ * For previously treated patients with 1 or 2 antihypertensive medications:~    * msDBP ≥ 90 and \< 100 mmHg, and/or msSBP ≥ 140 and \< 160 mmHg at Visit 1 AND~   * msDBP ≥ 100 and \< 120 mmHg, and/or msSBP ≥ 160 and \< 200 mmHg at Visit 2.~ * For previously treated patients with Atenolol 50 mg once daily alone more than 2 weeks consecutively at visit 1:~    * msDBP ≥ 100 and \< 120 mmHg, and/or msSBP ≥ 160 and \< 200 mmHg.~* Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).~Exclusion Criteria:~* Patients that previously participated in any Aliskiren study.~* Inability to receive or completely replace all previous antihypertensive medications with Atenolol 50 mg once daily for a period of 2 weeks as required by the protocol.~* Patients on 1 (other than Atenolol 50 mg once daily) or 2 antihypertensive drugs with msDBP ≥ 100 mmHg and/or msSBP ≥ 160 mmHg at Visit 1.~* Patients on 3 or more antihypertensive drugs at Visit 1.~* Pregnant or nursing (lactating) women, when pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (≥ 5 mIU/mL).~* Sexually active female patients who are not using effective contraceptive methods.~* Serum potassium \<3.5 mEq/L (mmol/L) or \> 5.5 mEq/L at Visit 1.~* Second or third degree heart block with or without a pacemaker, or other potentially life-threatening or symptomatic arrhythmia current or by history.~* History of noncompliance to medical regimens or unwillingness to comply with the study protocol.~Other protocol-defined inclusion/exclusion criteria may apply",,,0.989489,10,230.0,1.0,COMPLETED,1.74,0.0,0,0
